Peptide OEM manufacturing: the end-to-end workflow from inquiry to commercial production

OEM peptide manufacturing is the workflow where a brand or pharmacy contracts a manufacturer to produce a custom peptide product under the buyer's specifications and labeling, rather than buying off-the-shelf catalog material. The workflow runs longer and involves more decision points than a standard catalog purchase, and buyers new to OEM procurement often misjudge the timeline or skip stages that matter for downstream quality.

This guide walks through the six stages of a typical OEM peptide workflow at Vialdyne, with realistic timeline ranges and deliverables for each.

Stage 1: RFQ (Request For Quote), Day 0

The workflow starts with a Request For Quote that should include:

• The peptide name and sequence (or close-enough description if working from a published protocol)
• Target HPLC purity specification (≥99.0% is the Vialdyne baseline; ≥99.5% available as an upgrade for buyers who want extra margin)
• Desired counter-ion (acetate by default, see our acetate vs TFA guide)
• Vial fill size and total order quantity
• Optional modifications (PEG, lipidation, acetylation, copper coordination)
• Target destination market (regulatory framework affects the documentation scope)
• Intended use case (research / compounding pharmacy / finished cosmetic product / OEM finished product)
• Whether sterile-filled vials are required

Buyers without complete specifications are welcome to send what they have, Vialdyne's regulatory team helps fill the gaps during the inquiry conversation.

Stage 2: NDA and quote, Days 1-3

For custom sequences or proprietary formulations, Vialdyne countersigns a mutual NDA within one business day of receipt. After NDA, the regulatory team delivers a written quote covering:

• Unit price at the requested quantity
• MOQ for the specific sequence (varies by sequence length and synthesis complexity)
• Lead time for first sample shipment and for commercial production
• Documentation scope included in the standard release packet
• Optional add-on testing (LAL endotoxin, USP <61>/<62> microbial limits, stability, sequence verification by LC-MS/MS)
• INCOTERMS options (DDP / DAP / FCA / EXW) and approximate shipping cost ranges
• Regulatory advisory specific to the destination market

Quote turnaround is typically 12-24 hours during the working week. The first reply comes from a regulatory team member, not an auto-quote system.

Stage 3: Sample synthesis and validation, Weeks 1-4

For new sequences or first-time supplier qualification, Vialdyne runs pilot-scale synthesis at gram scale before committing to commercial production. The pilot batch is released with the full analytical packet:

• HPLC chromatogram with peak-integration purity
• ESI mass spec confirming molecular weight
• Sequence verification by LC-MS/MS (for peptides >15 amino acids, see our BPC-157 vs TB-500 article for why this matters)
• Water content, counter-ion, and any add-on tests specified in the quote

Sample shipment is typically 50-500 mg of finished material, sufficient for the buyer's in-house validation work (bioassay, downstream-formulation testing, regulatory sample submission). Sample-stage MOQ depends on the molecule; for the GLP-1 class the typical minimum is 5-10 g of bulk material because the synthesis cost amortization requires meaningful scale.

The buyer reviews the sample-batch documentation and runs whatever in-house validation tests the workflow requires. Sign-off on the sample batch is the prerequisite for moving to commercial production.

Stage 4: Formulation and packaging development, Weeks 4-8 (parallel)

For OEM finished products (sterile-filled vials, cosmetic finished formulations, multi-peptide blends), this stage runs in parallel with sample synthesis. Key decisions:

• Fill format: lyophilized vial, sterile-filled vial under ISO 7/8 cleanroom conditions, multi-dose vial with preservation, ampoule, prefilled syringe
• Vial size: standard fills (2/5/10/15/20/30/50 mg are most common) or custom, see our Tirzepatide product page for an example of an 12-fill range
• Secondary packaging: brand-labeled carton, inserts (IFU), language localization, regulatory disclaimers per destination market
• For cosmetic OEM: INCI naming verification, EU CPNP-compatible documentation, finished-product stability protocol
• For compounding pharmacy OEM: USP <85> endotoxin specification, USP <71> sterility for filled vials, USP <790> particulate matter

The packaging-development stage is where most OEM timelines extend beyond initial expectations. Brands that bring partial specifications to this stage iterate longer than brands that come prepared.

Stage 5: Commercial production, Weeks 8-14 (first run)

Once sample-batch sign-off and packaging-development sign-off are both complete, commercial production runs. Timeline varies by scale:

• Pilot commercial (50-500 g): 14-21 days from production start
• Standard commercial (1-10 kg): 21-35 days
• Large commercial (10+ kg): 35-60 days with potential split across multiple synthesis runs

The released-batch documentation packet for commercial production matches the sample-batch scope plus any add-on tests specified in the original quote. Shipment uses validated cold-chain logistics with continuous temperature monitoring throughout transit.

Stage 6: Recurring-order operations, Months 4+

Repeat orders against an established synthesis route and validated documentation compress significantly:

• Lead time: 10-14 days vs. 21-35 days for first-time orders
• Pricing: tiered against forecasted quarterly or annual volume
• Inventory: Vialdyne holds released-batch inventory against forecast for the largest commercial buyers, effectively compressing lead time to "next available shipment date" rather than "production start + lead time"
• Documentation: full COA and analytical packet on every batch; no re-validation work needed because the synthesis route is locked

The recurring-order phase is where the economics of OEM peptide procurement actually become favorable versus catalog purchase. First-run economics are dominated by the development overhead; recurring economics reflect the marginal cost of additional production.

What separates a good OEM partner from a transactional supplier

The OEM workflow involves dozens of decision points where the manufacturer's input meaningfully affects the buyer's downstream outcomes. A good OEM partner:

• Brings regulatory awareness to every stage rather than leaving it to the buyer
• Documents decisions in writing so the brand owns the development record
• Maintains stability data on the specific formulation, not generic class data
• Supports the brand's downstream customer-service needs (technical questions, regulatory inquiries from end-customers, label revisions)
• Holds released-batch inventory against forecast to support the brand's go-to-market timing

If the manufacturer treats the OEM relationship as a series of one-off transactions rather than an ongoing commercial partnership, the brand ends up doing the regulatory and quality work themselves, defeating the operational purpose of OEM in the first place.